November 10-12, 2026 | Boston, MA

www.protein-design-engineering-summit.com

REGISTER BY AUGUST 28 TO SAVE UP TO $1,000

Protein Design & Engineering in Biopharma Summit

Engineering the Next Generation of Therapeutic Proteins

Harnessing Computational, Structural & Biophysical Insight to Design, Engineer & Optimize Proteins with Enhanced Function, Therapeutic & Developability Potential

Expert Speakers Include:

Lauren Ely
Senior Director, Lead Discovery & Protein Engineering
CSL

Ertan Eryilmaz
Vice President, Biologics
InduPro

Ronnie Wei
Vice President, Biologics Discovery & Development
ModeX Therapeutics

Karen Conrad
Scientific Associate Director, Protein Science, Structural Biology
Takeda

Yao Fan
Director, Protein Design & Optimization
Tectonic Therapeutic

Ning Li
Vice President, Discovery
Versatope Therapeutics

+1 617 455 4188 info@hansonwade.com
www.protein-design-engineering-summit.com

hansonwade

Introducing the Protein Design & Engineering in Biopharma Summit

Protein Design & Engineering in Biopharma Summit

November 10-12, 2026 | Boston, MA

Advances in protein language models, generative design, structural biology, high-throughput experimentation, and protein analytics are accelerating the discovery of novel therapeutic proteins. However, identifying a promising sequence is only the beginning. The next hurdle is engineering molecules with the stability, functionality, developability, manufacturability, and *in vivo* performance needed to become successful drugs.

To this end, the inaugural **Protein Design & Engineering in Biopharma Summit** unites 80+ carefully selected leaders of **Protein Engineering**, **Computational Biology**, **Structural Biology**, **Biophysics**, **Developability** and, **Biologics R&D**. Designed as an intimate, industry-focused forum, the meeting moves beyond broad AI discussions to **examine the complete Design-Build-Test-Learn cycle**, connecting rational design and predictive modelling with experimental validation and therapeutic translation.

Join peers to:

- Accelerate rational protein and *de novo* antibody design using AI and generative modelling to optimize stability, function, developability and manufacturability earlier in discovery
- Benchmark computational and wet-lab workflows to shorten iteration cycles by integrating structural biology, biophysics and experimental validation to improve design predictability
- Learn how leading organizations are building *in silico* and hybrid protein design and engineering platforms to scale first- and best-in-class novel therapies

Join a highly curated community of protein science and biologics leaders, for three days of technical exchange focused on one shared challenge: **translating better protein designs into better therapeutic candidates through smarter rational design and *de novo* workflows**.

What's On in 2026?

80+
Senior Biopharma Protein & Biologic Science Attendees

40+
Rational Design & *De Novo*-Enabling Biotherapeutics Companies

7+
Hours of Dedicated Networking with Wet & Dry Lab Experts

2+
Closed Door Platform & Developmentability-Focused Workshops

Join Case-Study Led Discussion Across the Entire DBTL Cycle:



DESIGN next-generation proteins using AI, protein language models, generative modelling and rational engineering approaches to navigate sequence and structural space with greater precision

BUILD therapeutic candidates across antibodies, TCEs, bispecifics, trispecifics, enzymes and emerging protein modalities, optimizing function from initial concept through candidate generation

TEST protein performance through structural biology, biophysics, protein characterization and high-throughput experimental validation to improve design predictability and translational confidence

LEARN how leading organizations are accelerating Design-Build-Test-Learn cycles to engineer affinity, specificity, stability, developability, manufacturability and *in vivo* performance earlier in discovery

+1 617 455 4188 info@hansonwade.com
www.protein-design-engineering-summit.com
hansonwade

Your Expert Speakers

Alex Nisthal
Director, Protein Engineering
Xencor

Ben Meinen
Investigator, Head of Protein Design
AI Proteins

Bhupal Ban
Director of Antibody Discover, Protein Engineering & Development
Crossbow Therapeutics

Ertan Eryilmaz
Vice President, Biologics
InduPro

James Bowman
Chief Technology Officer
AI Proteins

Jason Lajoie
Director, Protein Engineering
Deck Bio

Karen Conrad
Scientific Associate Director, Protein Science, Structural Biology
Takeda

Lauren Ely
Senior Director, Lead Discovery & Protein Engineering
CSL

Melissa Geddie
Senior Vice President, Drug Discovery
Diagonal Therapeutics

Ning Li
Vice President, Discovery
Versatope Therapeutics

Qiang Yang
Director, Protein Engineering & Conjugation
OncoC4

Rajeeva Singh
Senior Principal Research Scientist, Biologics Drug Product Development
AbbVie

Ronnie Wei
Vice President, Biologics Discovery & Development
ModeX Therapeutics

Stephen Harper
Senior Director, *In Silico* Biologics
Immunocore

Vanina Chiarpotti
Computational Investigator
AI Proteins

Vladimir Voynov
Head, Discovery Biologics
Fable Therapeutics

Yao Fan
Director, Protein Design & Optimization
Tectonic Therapeutic

Ye Che
Senior Director, Global Head of Protein Structure & Biochemistry
GSK

> "I liked that it was a very close community and I could make conversation with almost all participants. I loved the wet lab round table discussion sessions, and learnt a lot even from these informal activities."
>
> **Past Attendee, 3rd Biophysics for Drug Discovery Summit 2026**

Pre-Conference Workshop Day
Tuesday, November 10

Check-In & Light Breakfast — 8.00

Workshop A — 9.00-12.00

Closing the Gap Between AI Designed Proteins & Functional Molecules Through High Quality Data Integration, Experimental Validation & Cross Functional Collaboration

This workshop will feature deep dive sessions on:

From Design to Optimization: Building Integrated Platforms for Functionalizing *De Novo* Proteins

- Addressing the unique challenges of producing and testing designed proteins
- Transitioning from designing for functional exploration to designing for optimization
- Coordinating multidisciplinary teams to measure diverse properties and accelerate design-build-test-learn cycles

Building Curated Databases to Fine-Tune Property-Prediction Models for Designed Proteins

- Bridging the wet- and dry-lab divide to prioritize and plan data generation
- Assessing workflow maturity and data quality before model fine-tuning
- Designing curated datasets that support reliable prediction of protein properties

Workshop Leaders

James Bowman
Chief Technology Officer
AI Proteins

Vanina Chiarpotti
Computational Investigator
AI Proteins

Lunch Break & Networking — 12.00

Workshop B — 1.00 - 4.00

Designing for Developability & Manufacturability from Day One to Improve Stability, Scalability & Reduce Late-Stage Risk in Biologic Development

Late-stage failures driven by aggregation, instability, and manufacturability issues continue to impact biologics pipelines, often because developability is overlooked during early design. As organizations aim to reduce downstream re-engineering, this workshop will explore how to embed developability and CMC considerations earlier through better data strategies, integrated screening, and stronger alignment between discovery and CMC teams to select candidates that are both functional and scalable.

This workshop will focus on:

- **How to identify developability risks** such as aggregation, viscosity, instability and, poor expression earlier in design workflows using physicochemical and biophysical indicators
- **How to integrate developability screening** with sequence design and candidate selection to prioritize molecules that are stable at high concentration and suitable for manufacture
- **How to improve data quality for developability prediction**, including use of representative formulation conditions and more consistent screening assays
- **How to embed manufacturability considerations**, such as expression purification and, formulation constraints earlier to reduce downstream re-engineering
- **How to improve alignment between discovery and CMC teams** to enable better decision making and smoother progression from design to development

Workshop Leaders

Yao Fan
Director, Protein Design & Optimization
Tectonic Therapeutic

Ertan Eryilmaz
Vice President, Biologics
InduPro

End Pre-Conference Workshop Day — 4.00

Conference Day One
Wednesday, November 11

8.00 **Check-In & Light Breakfast**

Bhupal Ban
Director, Antibody Discovery, Protein Engineering & Development
Crossbow Therapeutics

8.50 **Chair's Opening Remarks**

Harness AI, Generative Modelling, & Computational Workflows to Accelerate Rational Protein Design & Improve Candidate Quality at Scale

Ronnie Wei
Vice President, Biologics Discovery & Development
ModeX Therapeutics

9.00 **Reviewing a Function-First Approach to Designing Multispecifics & T-Cell Engagers**

- Translate therapeutic intent and disease biology into fit-for-purpose multispecific architectures, rather than starting with a preferred molecular format
- Examine how target combination, geometry, affinity, valency, and immune-cell engagement interact to determine coordinated function and therapeutic performance
- Explore how computational, structural, and experimental workflows can be integrated to reduce design space, accelerate optimization, and improve developability and translational potential

9.30 **Panel Discussion: De Risking *De Novo* & Computational Protein Design & Engineering to Build Repeatable Decision Grade Platforms for Faster Pipeline Progression**

- Where has computational design actually moved the needle, and how are you proving it internally to speed up drug pipelines?
- How to control for data quality and biological reality in ML-driven design loops? And what specific changes have you made to your data generation strategy to make it truly usable for training models?
- How are you deciding what to prioritize today across *de novo* design, optimization workflows, and engineering, given they sit at different points in the hype cycle?

Yao Fan
Director, Protein Design & Optimization
Tectonic Therapeutic

Bhupal Ban
Director, Antibody Discovery, Protein Engineering & Development
Crossbow Therapeutics

James Bowman
Chief Technology Officer
AI Proteins

Stephen Harper
Senior Director, *In Silico* Biologics
Immunocore

10.15 **Exploring Data-Driven *In Silico* Design of Enhanced-Affinity TCRs**

- Affinity maturation of TCR biologics is increasingly enabled by the integration of machine learning, high-throughput screening, and biophysical data
- We combine sequence-based models trained on NGS and screening outputs with structure-based approaches informed by historical Biacore and structural datasets
- This integrated framework prioritizes mutations with a high probability of improving affinity, accelerating design cycles while maximizing the value of legacy experimental data

10.45 **Morning Break & Speed Networking**
An opportunity to network, discuss and collaborate with like-minded leaders of the protein sciences, design and engineering community

Conference Day One
Wednesday, November 11

Translating Promising Molecules to Real Drugs by Embedding Developability into Protein Design & Engineering to Improve Scalability, Manufacturability & Downstream Success

Vladimir Voynov
Head, Discovery Biologics
Fable Therapeutics

11.45 **Round Table: Building Effective AI-Enabled Design-Build-Test-Learn Workflows for Protein Engineering**

- Generating high-quality experimental data to improve predictive protein design models
- Creating rapid feedback loops between computational design and wet-lab validation
- Integrating developability screening earlier in discovery to improve downstream success
- Lessons learned from combining machine learning and biologics discovery teams under one workflow

Rajeeva Singh
Senior Principal Research Scientist, Biologics Drug Product Development
AbbVie

12.15 **CMC Developability Screening of Discovery Candidates**

- Physicochemical developability screening for optimal drug candidate selection
- Accelerated stability studies using small sample amounts

12.45 **Lunch Break & Networking**

Discover Emerging Approaches Across Mini-Proteins & Vaccines to Improve Functional Activity & Candidate Performance

Ben Meinen
Investigator, Head of Protein Design
AI Proteins

1.45 **Designing Miniprotein Medicine: Efficient, Constraint-Aware Pipelines for *De Novo* Miniprotein Design**

- *De novo* design models, trained on natural protein distributions, exhibit recurring failure modes such as poor designability when applied unconstrained to miniproteins
- We introduce a constraint-aware pipeline that filters and steers generation to mitigate these failure modes while preserving sequence diversity and designability

Ye Che
Senior Director, Global Head of Protein Structure & Biochemistry
GSK

2.15 **Structural Design Strategies for Developing Next-Generation Vaccines**

- Learn how structural biology enables the identification and design of stable, immunogenic epitopes, using technologies like cryo-EM and X-ray crystallography to tailor antigens that can trigger robust immune responses
- Discover how vaccine candidates are designed by optimizing antigen structures, addressing challenges like antigenic variation, and focusing on conserved regions to enhance broad protection against evolving pathogens
- Explore how structural insights are leading to the design of vaccines against "undruggable" or challenging targets, where understanding protein folding and conformational flexibility is key to developing novel immunogens

2.45 **Afternoon Break & Scientific Poster Session**
As the wet- and dry-lab development into novel protein biotherapeutics continues to progress from strength to strength, it is more important than ever to collaborate and learn with your peers, as we continue to advance these therapies to patients in need. Join your colleagues to share your latest data and have the first look into what your peers are working on!

Conference Day One
Wednesday, November 11

Reviewing Real World Case-Studies in Design & Engineering to Streamline Future Design Decisions & Candidate Quality

Qiang Yang
Director, Protein Engineering & Conjugation
OncoC4

3.45 **Session Reserved for OncoC4**
- Presentation Details to be Announced

4.15 **Engineering Proteins with Purpose: A Discovery Framework for Building Therapeutic Candidates**

Ning Li
Vice President, Discovery
Versatope Therapeutics

- Begin with purpose: Define the therapeutic objective and target product profile before optimizing the molecule
- Design for learning: Build experimental strategies that reduce uncertainty and guide the next discovery decision
- Optimize the whole candidate: Balance molecular performance, developability, manufacturability, and timelines to advance therapeutics with the greatest chance of success

Bhupal Ban
Director, Antibody Discovery, Protein Engineering & Development
Crossbow Therapeutics

4.45 **Chair's Closing Remarks**

4.55 **End of Conference Day One**

> "I enjoyed intimate workshops and connecting with colleagues from around the protein industry. The talks were high quality, and interactive roundtables were very helpful in understanding the different ways colleagues are approaching the same types of challenges."
>
> **Past Attendee, 3rd Biophysics for Drug Discovery Summit 2026**

> "This meeting offered a quality audience among the room and speakers, enabling us to understand the value we bring and drive business"
>
> **Past Sponsor, Structure-Based Drug Design Summit**

Conference Day Two
Thursday, November 12

8.00 Check-In & Light Breakfast

Jason Lajoie
Director, Protein Engineering
Deck Bio

9.00 **Chair's Opening Remarks**

Accelerating Bispecific, Trispecific & T-Cell Engager Design & Optimization Through Hybrid *In Silico* & Experimental Strategies to Enhance Developability, Function & Translation

Alex Nisthal
Director, Protein Engineering
Xencor

9.10 **Designing Around Bispecific Complexity in T-Cell Engagers to Improve Scalability Robustness & Design Flexibility Across Multi-Chain Formats**

- What enables high-throughput T-cell engager design using asymmetric formats, and how does avoiding heterodimerization improve tractability while limiting more complex architectures?
- What challenges arise when scaling to true bispecific and trispecific formats, and how do chain pairing and misassembly constrain throughput and design flexibility?
- How can next-generation scaffolds overcome pairing issues to enable more robust multi-chain molecule design?

Melissa Geddie
Senior Vice President, Drug Discovery
Diagonal Therapeutics

9.40 **Round Table: Closing the Design-Build-Test-Learn Loop for Multispecific Antibody Discovery & Candidate Selection**

- Combining computational and experimental workflows to identify and refine bispecific candidates
- Determining what data is most valuable for informing and improving protein design models
- Building effective feedback loops between *in silico* prediction and experimental validation
- Key challenges in translating engineered multispecific antibodies from discovery through candidate selection

10.40 Morning Break & Networking

Benchmark Hybrid Computational & Wet-Lab Workflows to Improve Design-Build-Test Iteration Cycles & Improve Candidate Success

Ertan Eryilmaz
Vice President, Biologics
InduPro

11.40 **Biological Proximity to Therapeutic Design: Integrating Computational Approaches with High-Throughput Experimentation Quality**

- Combining computational analysis with experimental interrogation to uncover biologically relevant protein relationships and guide therapeutic hypotheses
- Using rapid probe generation and high-throughput testing to inform target selection, molecular design, and functional optimization
- Applying iterative design-build-test workflows to translate biological insights into differentiated therapeutic concepts

Conference Day Two
Thursday, November 12

Lauren Ely
Senior Director, Lead Discovery & Protein Engineering
CSL

12.10 Round Table: Optimizing Design-Build-Test-Learn Workflows to Improve Iteration Speed Decision-Making & Data Value

- Where do bottlenecks occur in design-build-test-learn workflows and how do differences in timing between computational and experimental teams' slow iteration cycles?
- How can closer integration between wet-lab and data science improve data handoffs, reduce delays and enable faster iteration?
- How can teams prioritize experiments that generate high value data to improve decisions and maximize learning in each cycle?

1.10 Lunch Break & Networking

Integrate Structural Biology, Biophysics, & High-Throughput Experimental Validation for Improved Predictability & Translational Success

2.10 Panel Discussion: Applying Structural Biology Insights to Improve Functional Prediction & Translational Success in Protein Design

- Assessing the limitations of structure prediction methods such as AlphaFold and exploring how moving beyond static models to dynamic systems can improve protein design outcomes
- Examining how cryo-EM data and co-folding models can be combined to enhance prediction of multi-component interactions in complex biologics
- Understanding what drives the gap between structural accuracy and functional performance, and how to better translate *in silico* designs into biological activity

Ye Che
Senior Director, Global Head of Protein Structure & Biochemistry
GSK

Karen Conrad
Scientific Associate Director, Protein Science - Structural Biology
Takeda

Karen Conrad
Scientific Associate Director, Protein Science - Structural Biology
Takeda

3.10 Protein Design to Enable Structural Biology of Membrane Proteins & GPCRs: From Soluble Analogues to Conformationally Stabilized Receptors

- Surveying the protein engineering objectives that enable structural studies of membrane proteins and GPCRs, including the use of soluble analogues and stabilized receptor constructs
- Prioritizing design strategies that deliver structural biology value by improving construct tractability, conformational control, and downstream drug discovery impact

Jason Lajoie
Director, Protein Engineering
Deck Bio

3.40 Chair's Closing Remarks

3.50 End of the Protein Design & Engineering in Biopharma Summit

Designed for R&D, Built for Collaboration - Partner With Us

Protein Design & Engineering in Biopharma Summit
November 10-12, 2026 | Boston, MA

Your Curated Platform to Foster Protein Sciences Connections & Engineer the Right Outcomes

Therapeutic protein discovery is becoming increasingly multidisciplinary, with teams building integrated workflows spanning computational design, structural biology, biophysics, high-throughput screening, developability assessment, and CMC readiness.

As these capabilities expand, identifying the right partners has become a strategic priority. Organizations are seeking rational and *de novo* design platforms and expertise that improve design predictability, accelerate characterization, remove experimental bottlenecks, and enable faster progression from candidate to clinic.

The **Protein Design & Engineering in Biopharma Summit** brings together a curated audience of senior scientific leaders driving protein engineering strategy and platform investment across biopharma. This creates a valuable opportunity to engage decision-makers directly and demonstrate how your wet-lab, *in silico* or manufacturing solutions can accelerate the discovery, optimization, and delivery of next-generation protein therapeutics.

- Get in Front of Protein Design Decision-Makers
- Showcase Your Expertise Across the DBTL Workflow
- Forge Partnerships Across Wet, Dry Lab & Hybrid Teams
- Benefit From Biologic & Next Generation Therapy Market Intelligence

Attendee Seniority*



- 9% CxO
- 5% Vice President
- 32% Director
- 11% Head/Manager/Lead
- 40% Scientist
- 3% Other

Audience Composition*



*Statistics average taken from Biophysics for Drug Discovery Summit 2026

Get Involved

Tom Conibear
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.protein-design-engineering-summit.com

Tel: +1 617 455 4188

Email: info@hansonwade.com

DISCOVER how leading wet and dry lab biopharma teams are integrating protein design, structural biology, biophysics and high-throughput experimentation to accelerate the development of next-generation therapeutics

BENCHMARK strategies across the full Design-Build-Test-Learn cycle to improve protein function, stability, developability and translational success

CONNECT with protein engineers, computational biologists, structural biologists and biologics innovators to exchange ideas, forge collaborations and solve shared scientific challenges

Pharma & Biotech Pricing*	Register & Pay By Friday, August 28	On the Door Price
Conference + 2 Workshops	$3,397 **(Save $1,000)**	$4,397
Conference + 1 Workshop	$2,998 **(Save $750)**	$3,748
Conference Only	$2,599 **(Save $500)**	$3,099
Academic Pricing**	Register & Pay By Friday, August 28	On the Door Price
Conference + 2 Workshops	$2,797 **(Save $1,000)**	$3,797
Conference + 1 Workshop	$2,498 **(Save $750)**	$3,248
Conference Only	$2,199 **(Save $500)**	$2,699
Solution & Service Provider Pricing	Register & Pay By Friday, August 28	On the Door Price
Conference + 2 Workshops	$4,297 **(Save $1,000)**	$5,297
Conference + 1 Workshop	$3,798 **(Save $750)**	$4,548
Conference Only	$3,299 **(Save $500)**	$3,799

*To be eligible for this price, the group or individual must be from a biotech, techbio or pharma company that has a publicly disclosed pipeline. They must not be outsourcing their pipeline or offer paid for products and/or partnering services. Please visit the website for full pricing options or email info@hansonwade.com

**To be eligible for this price, the group or individual must be full-time academic(s). Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Wyndham Boston Beacon Hill
5 Blossom St, Boston, MA 02114, United States
For further information or assistance, please visit:
www.wyndhambeaconhill.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom